

Anti-Mouse CD18 SAFIRE Purified

Catalog Number :10212-25

RUO: For Research Use Only. Not for use in diagnostic procedures.

Product Information

Clone: M18/2

Format/Conjugate: SAFIRE Purified

Concentration: 1 mg/mL

Reactivity: Mouse

Laser: Not Applicable

Peak Emission: Not Applicable

Peak Excitation: Not Applicable

Filter: Not Applicable

Brightness (1=dim,5=brightest): Not Applicable

Isotype: Rat IgG2a, kappa

Formulation: Phosphate-buffered aqueous solution, pH7.2.

Storage: Product should be kept at 2-8°C.

Applications: FC, FA

Description

The M18/2 monoclonal antibody specifically binds to mouse CD18, a 95kDA integrin beta 2 glycoprotein. CD18 is expressed on all leukocytes with the highest density by NK and T cells. CD18 forms LFA-1 with CD11a, Mac-1 with CD11b and gp150/95 with CD11c. Through these interactions, CD18 has an important role in cellular adhesion. The M18/2 antibody is reported to stimulate Mac-1 and LFA-1 adhesion to their ligands and block tumor cell metastasis.

Preparation & Storage

The product should be stored undiluted at 4°C. Do not freeze. The monoclonal antibody was purified utilizing affinitychromatography. The endotoxin level is determined by LAL test to be less than 0.01 EU/μg of the protein.

Application Notes

The antibody has been analyzed for quality through the flow cytometric analysis of the relevant cell type. It is recommended that the reagent be titrated for optimal performance for each application.

References

1. Driessens, M. H., Van Hulten, P., Zuurbier, A., La Riviere, G., Roos, E. (1996). Inhibition and stimulation of LFA-1 and Mac-1 functions by antibodies against murine CD18. Evidence that the LFA-1 binding sites for ICAM-1,-2, and-3 are distinct.;Journal of leukocyte biology.;60(6), 758-765.
2. Zahalka, M. A., Naor, D. (1994). β2-Integrin dependent aggregate formation between LB T cell lymphoma and spleen cells: assessment of correlation with spleen invasiveness.;International immunology.;6(6), 917-924.
3. Isobe, M., Yagita, H., Okumura, K., Ihara, A. (1992). Specific acceptance of cardiac allograft after treatment with antibodies to ICAM-1 and LFA-1.;Science,255(5048), 1125-1127.